Why the study?
Does F-FDG PET show increased uptake in pulmonary lymphangitic carcinomatosis compared to normal lung tissue?
Does F-FDG PET show increased uptake in pulmonary lymphangitic carcinomatosis compared to normal lung tissue?
F-FDG PET shows diffuse increased uptake corresponding to the CT pattern of pulmonary lymphangitic carcinomatosis in lung cancer patients.
Answers are grounded in this paper and cite their sources.
F-FDG PET may aid detection of pulmonary lymphangitic carcinomatosis; hypothesis-generating and requires prospective validation.
OBJECTIVE: The purpose of this study was to evaluate the F-fluorodeoxyglucose (FDG) positron emission tomography (PET) uptake in pulmonary lymphangitic carcinomatosis identified on computed tomography (CT) in patients with lung cancer. METHODS: This was a retrospective analysis of F-FDG PET images in 7 patients (4 male and 3 female, mean age: 56.6 +/- 6.6 years) with lung cancer with a CT-based diagnosis of lymphangitic carcinomatosis. The F-FDG PET scans in a group of 7 patients (4 male and 3 female, mean age: 42.1 +/- 5.66 years) with normal chest CT scans served as a control group. Mean standardized uptake values (SUVs) were calculated based on average tumor uptake, initial injected activity, and body weight. RESULTS: The intensity of F-FDG uptake in diseased lung is significantly greater than in corresponding normal contralateral lung or in the lungs of normal controls (P = 0.003). The ratio of the SUV of lung with lymphangitic carcinomatosis to corresponding contralateral normal lung was significantly increased (P = 0.006), and the ratio of the SUV of mediastinal blood pool to lung with lymphangitic carcinomatosis was significantly decreased (P = 0.0002). CONCLUSION: There is diffuse increased FDG uptake in the lung corresponding to the CT pattern of lymphangitic carcinomatosis.
No takes yet. Share an insight, caveat, or question.
Digumarthy et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: